A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

NCT01252186 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemostasis
Oral Contraceptive

Interventions

DRUG: 91-day Levonorgestrel Oral Contraceptive
DRUG: 28-day Levonorgestrel Oral Contraceptive
DRUG: 28-day Desogestrel Oral Contraceptive

Sponsor

Teva Women's Health